Innovations In Clinical Neuroscience

CNS Summit 2016

A peer-reviewed, evidence-based journal for clinicians in the field of neuroscience

Issue link: http://innovationscns.epubxp.com/i/808251

Contents of this Issue

Navigation

Page 3 of 23

Innovations in CLINICAL NEUROSCIENCE [ V O L U M E 1 4 , N U M B E R 1 – 2 , J A N U A R Y – F E B R U A R Y 2 0 1 7 , S U P P L E M E N T ] S4 Artificial Intelligence/Machine Learning................................S5 • Evaluating the use of an artificial intelligence platform on mobile devices to measure adherence in subjects with an acute exacerbation of schizophrenia • NetraMark: predicting placebo and drug response for pharma B iomarkers and Imaging...................................................S5 • Comparison of actigraphy endpoints for estimating nocturnal scratching duration in patients with atopic dermatitis • Development of neurophysiological-based biomarkers for neurodegenerative disease and psychiatric disorders using EEG • Sleep staging based on a reduced montage using two EOG channels Computer-based Tools..................................................... S6 • [An] electronic (eCOA) prompted Yale Global Tic Severity Scale (YGTSS) with blinded internal scoring • [The] electronic self-report of the C-SSRS (eC-SSRS) places little burden on patients initially and even less with repeated administrations • The NetSCID: A validated web-based adaptive version of the SCID that improves diagnostic accuracy in mental health research Digital Medicine.............................................................S8 • Clinical trial of Clickotine ® , a Digital therapeutics ™ solution for smoking cessation: design and total health execution methodology • Development of neurophysiological-based biomarkers for neurodegenerative disease and psychiatric disorders using EEG • Evaluating the use of an artificial intelligence platform on mobile devices to measure adherence in subjects with an acute exacerbation of schizophrenia • Optimizing the mobile clinical trial: data collection through a web- based platform in telemedicine protocol Investigative Drug Compounds and Therapies........................ S9 • [The] AtEase study: treatment of military-related PTSD • [The] clinical development of ITI-007 for the treatment of schizophrenia • D 3 : deuterium drug development • Drug repositioning for neurological disorders using a sustained release formulation of exenatide • [The] effect of cholesterol on positive symptoms of schizophrenia Mobile Technology...............................................................S11 • Clinical trial of Clickotine ® , a Digital Therapeutics ™ solution for smoking cessation: design and total health execution methodology • Evaluating the use of an artificial intelligence platform on mobile devices to measure adherence in subjects with an acute exacerbation of schizophrenia • Optimizing the mobile clinical trial: data collection through a web- based platform in telemedicine protocol Patient Assessment and Adherence..................................... S12 • Are there reporting differences at screening on the Montgomery- Äsberg Depression Rating Scale (MADRS) between older and younger adults when using remote assessments? • Cultural adaptation of the Virtual Reality Functional Capacity Assessment Tool (VRFCAT) for use in the United Kingdom and Canada • Development of neurophysiological-based biomarkers for neurodegenerative disease and psychiatric disorders using EEG • Discrepancies between CGI-S score and PANSS item level scores— a n exploratory analysis................................................................... • [An] electronic (eCOA)-prompted Yale Global Tic Severity Scale (YGTSS) with blinded internal scoring • [The] electronic self-report of the C-SSRS (eC-SSRS) places little burden on patients initially and even less with repeated administrations • Evaluating the use of an artificial intelligence platform on mobile devices to measure adherence in subjects with an acute exacerbation of schizophrenia • NetraMark: predicting placebo and drug response for pharma • [The] NetSCID: a validated web-based adaptive version of the SCID that improves diagnostic accuracy in mental health research • Patients with psychiatric diagnoses indicate willingness to report suicidal ideation and behavior more honestly by self-report than in face-to-face interviews • Translation of the National Institutes of Health Stroke Scale (NIHSS) list of words: methodology and challenges Placebo Response.......................................................... S17 • Factors associated with response rate in inpatient schizophrenic participants • NetraMark: predicting placebo and drug response for pharma Rater Assessment and Training.......................................... S18 • Understanding rater preferences in services used to increase the reliability of clinical trials: a multi-national survey Trial Methodology/Study Protocol........................................ S18 • Could a paradigm shift in consumptive disorders research benefit patients and sponsors alike? A smoking cessation case study reinforces "the manner in which we look at things determines what we see!" • Discrepancies between CGI-S score and PANSS item level scores— an exploratory analysis • Evaluating the use of an artificial intelligence platform on mobile devices to measure adherence in subjects with an acute exacerbation of schizophrenia • Methodology and management of clinical trials with adaptive designs • NetraMark: predicting placebo and drug response for pharma • [A] reanalysis of the effects of protocol design and subject stipend on completion rates in Phase 1 studies in subjects with stable schizophrenia or schizoaffective disorder: Does money matter? • Toward a better understanding of informant contributions to schizophrenia trial quality: data from the encenicline cognitive impairment program • Understanding rater preferences in services used to increase the CNS Summit 2015—Abstracts of Poster Presentations October 7–11, 2015 • Boca Raton, Florida Volume 14 • Issue 1–2 • January–February 2017 • Supplement TABLE OF CONTENTS

Articles in this issue

Archives of this issue

view archives of Innovations In Clinical Neuroscience - CNS Summit 2016